Catalent, Inc. Announces Pricing of Its Initial Public Offering

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the pricing of its initial public offering of 42,500,000 shares of its common stock at $20.50 per share. The shares are expected to begin trading on the New York Stock Exchange on July 31, 2014 under the ticker symbol “CTLT,” and the offering is expected to close on August 5, 2014, subject to customary closing conditions. Catalent has granted the underwriters a 30-day option to purchase up to an additional 6,375,000 at the initial public offering price.

Help employers find you! Check out all the jobs and post your resume.

Back to news